TNFSF10 and cancer: Using a set of custom-designed TR3 variants (soluble and membrane-anchored) and a variety of transduction formats (standard transfection methods and adenoviral infection procedures), we connected findings initially discovered during the characterization phase of mesothelin-targeted TR3-based cancer therapeutics with native TRAIL biology.